On December 18, 2023, the Minister of Health announced the creation of the Canadian Drug Agency. According to the announcement, the Canadian Drug Agency (CDA) “will provide the dedicated leadership and coordination needed to make Canada's drug system more sustainable and better prepared for the future, helping Canadians achieve better health outcomes.” It will be built from the Canadian Agency for Drugs and Technologies in Health (CADTH), in partnership with provinces and territories. The CDA will build on CADTH’s mandate and functions, and will expand them, including improving appropriate prescribing and use of medications, and increasing pan-Canadian data collection and expanding access to drug and treatment data, including real-world evidence data.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and life sciences regulatory law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
PMPRB appoints Sharon Blady to Board and releases October 2024 NEWSletter
On October 17, 2024, the Minister of Health announced the appointment of Sharon Blady (the former Health Minister of Manitoba) to the Patented Medicine Prices Review Board (PMPRB).Read More -
Evolving pharmacy landscape signals more stringent regulatory scrutiny of “patient steering”
The pharmacy landscape has evolved considerably over the past year, shining a spotlight on pharmacy “patient steering”, the practice of directing patients to certain preferred pharmacies.Read More -
Government of Canada passes Pharmacare Act
On October 10, 2024, the Government of Canada announced that the Pharmacare Act received royal assent and came into force.Read More